AssetMark Inc’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $26.8M | Sell |
59,954
-30,529
| -34% | -$14.2M | 0.05% | 273 |
|
|
2025
Q4 | $41M | Buy |
90,483
+633
| +0.7% | +$273K | 0.08% | 188 |
|
|
2025
Q3 | $35.2M | Sell |
89,850
-2,541
| -3% | -$1.06M | 0.08% | 202 |
|
|
2025
Q2 | $41.1M | Buy |
92,391
+7,094
| +8% | +$3.27M | 0.1% | 176 |
|
|
2025
Q1 | $41.4M | Buy |
85,297
+5,432
| +7% | +$2.53M | 0.11% | 160 |
|
|
2024
Q4 | $32.2M | Sell |
79,865
-124,206
| -61% | -$57.6M | 0.09% | 183 |
|
|
2024
Q3 | $94.9M | Sell |
204,071
-176,283
| -46% | -$84.7M | 0.27% | 75 |
|
|
2024
Q2 | $178M | Sell |
380,354
-2,107
| -0.6% | -$915K | 0.55% | 39 |
|
|
2024
Q1 | $160M | Sell |
382,461
-4,937
| -1% | -$2.09M | 0.52% | 43 |
|
|
2023
Q4 | $158M | Sell |
387,398
-117,030
| -23% | -$43.2M | 0.57% | 39 |
|
|
2023
Q3 | $175M | Sell |
504,428
-6,743
| -1% | -$2.36M | 0.7% | 35 |
|
|
2023
Q2 | $180M | Sell |
511,171
-27,668
| -5% | -$9.32M | 0.71% | 35 |
|
|
2023
Q1 | $170M | Buy |
538,839
+137,127
| +34% | +$41.1M | 0.7% | 36 |
|
|
2022
Q4 | $116M | Buy |
401,712
+13,854
| +4% | +$4.22M | 0.5% | 46 |
|
|
2022
Q3 | $112M | Buy |
387,858
+380,279
| +5,018% | +$109M | 0.53% | 47 |
|
|
2022
Q2 | $2.14M | Buy |
7,579
+2,696
| +55% | +$722K | 0.01% | 345 |
|
|
2022
Q1 | $1.27M | Buy |
4,883
+3,062
| +168% | +$727K | 0.01% | 419 |
|
|
2021
Q4 | $400K | Buy |
1,821
+1,712
| +1,571% | +$333K | ﹤0.01% | 579 |
|
|
2021
Q3 | $20K | Sell |
109
-39
| -26% | -$7.62K | ﹤0.01% | 942 |
|
|
2021
Q2 | $30K | Sell |
148
-19
| -11% | -$3.97K | ﹤0.01% | 832 |
|
|
2021
Q1 | $36K | Buy |
167
+34
| +26% | +$7.47K | ﹤0.01% | 776 |
|
|
2020
Q4 | $31K | Sell |
133
-22
| -14% | -$5.05K | ﹤0.01% | 782 |
|
|
2020
Q3 | $42K | Sell |
155
-154
| -50% | -$42.5K | ﹤0.01% | 707 |
|
|
2020
Q2 | $90K | Buy |
309
+241
| +354% | +$65.3K | ﹤0.01% | 591 |
|
|
2020
Q1 | $16K | Sell |
68
-5
| -7% | -$1.15K | ﹤0.01% | 916 |
|
|
2019
Q4 | $16K | Buy |
+73
| New | +$14.8K | ﹤0.01% | 972 |
|
|
2018
Q4 | – | Sell |
-2,940
| Closed | -$567K | – | 1546 |
|
|
2018
Q3 | $567K | Sell |
2,940
-88
| -3% | -$15.7K | 0.01% | 341 |
|
|
2018
Q2 | $515K | Sell |
3,028
-113
| -4% | -$17.5K | 0.01% | 344 |
|
|
2018
Q1 | $512K | Sell |
3,141
-14,041
| -82% | -$2.29M | 0.01% | 341 |
|
|
2017
Q4 | $2.58M | Buy |
17,182
+17,134
| +35,696% | +$2.54M | 0.03% | 245 |
|
|
2017
Q3 | $7K | Buy |
48
+37
| +336% | +$5.57K | ﹤0.01% | 1103 |
|
|
2017
Q2 | $1K | Buy |
+11
| New | +$1.32K | ﹤0.01% | 1334 |
|
|
2017
Q1 | – | Sell |
-73
| Closed | -$5K | – | 1446 |
|
|
2016
Q4 | $5K | Sell |
73
-40
| -35% | -$3.25K | ﹤0.01% | 1048 |
|
|
2016
Q3 | $10K | Buy |
113
+112
| +11,200% | +$10.6K | ﹤0.01% | 980 |
|
|
2016
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 1277 |
|
|
2016
Q1 | $0 | Sell |
1
-43
| -98% | -$3.89K | ﹤0.01% | 1422 |
|
|
2015
Q4 | $6K | Buy |
44
+32
| +267% | +$3.86K | ﹤0.01% | 953 |
|
|
2015
Q3 | $1K | Buy |
+12
| New | +$1.54K | ﹤0.01% | 691 |
|
Other funds holding VRTX
VCM
VPM
AssetMark Inc's VRTX Position: Q1 2026 in Review
AssetMark Inc reduced its Vertex Pharmaceuticals (VRTX) stake by 34% in Q1 2026, selling an estimated $14.2M and leaving 59,954 shares worth $26.8M. The position accounts for 0.05% of the portfolio, ranked #273.
AssetMark Inc first reported a position in VRTX in Q3 2015 and has held it in 38 quarters since. The position peaked at $180M in Q2 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- AssetMark Inc held 59,954 shares of Vertex Pharmaceuticals worth $26.8M as of Q1 2026.
- AssetMark Inc sold 30,529 Vertex Pharmaceuticals shares in Q1 2026, an estimated $14.2M.
- Vertex Pharmaceuticals made up 0.05% of AssetMark Inc's portfolio in Q1 2026, its #273 holding.
- AssetMark Inc first reported a position in Vertex Pharmaceuticals in Q3 2015 and has held it in 38 quarters since.
- AssetMark Inc's Vertex Pharmaceuticals position peaked at $180M in Q2 2023.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.